LEXINGTON, Mass. -- (BUSINESS WIRE) -- Cubist Pharmaceuticals issued the following statement today regarding the U.S. Food and Drug Administration’s (FDA) new voluntary plan to phase out the use of certain antibiotics for enhanced food production.
“As the global leader in the research and development of antibiotics to treat serious and life-threatening pathogens that impact humans, Cubist strongly supports the FDA’s plan to phase out the use of certain antibiotics in the food chain,” said Mike Bonney, Cubist’s Chief Executive Officer. “This is a judicious and responsible approach to a complex, global issue. The inappropriate use of antibiotics as growth promoters in animals encourages the development of antibiotic-resistant bacteria, that, when transferred to humans, can result in drug resistant infections that have become a serious global public health threat. We are reassured by the FDA’s recent action and by their - and Congress’ - ongoing commitment to address the emerging public health crisis of antibiotic resistance.”
About Cubist’s Commitment to Antibiotic R&D
Cubist has a significant commitment to global public health through its leadership in the research, development and commercialization of antibiotics to treat serious and life-threatening infections caused by a broad range of increasingly resistant bacteria. The Company hopes to deliver at least four new antibiotics in support of the Infectious Diseases Society of America (IDSA) goal of 10 new antibiotics by 2020. Cubist is investing over $300M USD in 2013 on antibacterial R&D and approximately 75% of its employee base is focused on the research, development, commercialization and support of antibiotics.
Cubist Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Massachusetts, with a central international office located in Zurich, Switzerland. Additional information can be found at Cubist’s web site at www.cubist.com.